CXCL10 changes are linked to ruxolitinib response
Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study
What the study says
A phase 2 trial studied whether immune signals change alongside repigmentation during ruxolitinib treatment. Sixty adults were assigned to ruxolitinib cream or vehicle for 24 weeks, followed by active treatment. Researchers observed reductions in CXCL10, an inflammation-related protein, in blood and affected skin. These changes correlated with improvements in vitiligo scores. The findings connect a biological pathway with clinical response and could inform future biomarker research. They do not establish a routine blood test or predict an individual person's treatment outcome.
How to interpret this finding
Small mechanistic study. Correlation does not validate an individual response predictor.
Research findings describe groups of participants. Discuss their relevance to your own care with your clinician.
References & original sources
These links identify the actual paper, its indexed record and available full text.
Image source & reuse
Diane A. Reid (Photographer) / National Cancer Institute
Context photograph: a National Cancer Institute scientist pipetting samples. Not photographed during this vitiligo study.
View original image sourcePublic domain
